台湾低至中度砷暴露地区饮用水砷暴露与慢性肾脏病发病:14年前瞻性研究
该研究在台湾东北部砷暴露流行区招募6093名40岁及以上参与者,随访1998至2011年,发现井水砷浓度≥10μg/L与慢性肾脏病(CKD)发病呈剂量依赖关联,趋势P=0.02;尿砷浓度较高与蛋白尿患病率升高相关。
要点
- 井水砷≥10μg/L与CKD发病风险增加相关,且存在剂量依赖趋势。
- 尿砷浓度较高与蛋白尿患病率升高相关。
- 砷暴露与肾脏疾病的关联在女性中可能更强。
核心结论
- 饮用水砷浓度≥10μg/L与CKD发病存在时间关联,且井水砷浓度与肾脏疾病呈剂量依赖关联。
研究设计与样本
- 长期前瞻性观察性研究,纳入台湾东北部砷暴露流行区6093名40岁及以上参与者。
主要发现
- 共识别1104例新发肾脏疾病,其中447例CKD,发病率分别为166.5和67.4每10^4人年。
- 以井水砷≤10.0μg/L为参照,10.1-49.9、50.0-149.9、≥150.0μg/L组CKD发病的多变量调整HR分别为1.12(95%CI 0.88-1.42)、1.33(95%CI 1.03-1.72)、1.33(95%CI 1.00-1.77),趋势P=0.02。
- 尿砷浓度第50-75百分位和第75-100百分位区间分别与蛋白尿患病率升高50%和67%相关。
- 砷浓度与肾脏疾病的关联在女性中更强(交互作用P=0.06)。
关键数值与推荐
- 井水砷浓度50th、75th、90th百分位分别为28.0、92.8、295.7μg/L。
- 蛋白尿定义为蛋白排泄≥200mg/g。
- 肾脏疾病和CKD结局基于ICD-9诊断代码从台湾全民健康保险数据库获取。
临床怎么用
- 在低至中度砷暴露地区,应关注饮用水砷浓度≥10μg/L对CKD发病风险的影响。
- 监测尿砷和蛋白尿可能有助于识别砷暴露相关肾损伤高风险人群。
局限性
- 肾脏疾病和CKD结局基于诊断代码,无肾小球滤过率数据。
- 未测量其他重金属。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arsenic exposure is associated with decreased kidney function. The association between low to moderate arsenic exposure and kidney disease has not been fully clarified. STUDY DESIGN: The association between arsenic exposure from drinking water and chronic kidney disease (CKD) was examined in a long-term prospective observational study. SETTING & PARTICIPANTS: 6,093 participants 40 years and older were recruited from arseniasis-endemic areas in northeastern Taiwan. Arsenic levels were 28.0, 92.8, and 295.7μg/L at the 50th, 75th, and 90th percentiles, respectively. PREDICTOR: Well-water arsenic and urinary total arsenic (inorganic plus methylated arsenic species) concentrations, adjusted for urinary creatinine concentration. OUTCOMES: Kidney diseases (ICD-9 codes: 250.4, 274.1, 283.11, 403.*1, 404.*2, 404.*3, 440.1, 442.1, 447.3, or 580-589) and CKD (ICD-9 code: 585) ascertained using Taiwan's National Health Insurance database 1998 to 2011. MEASUREMENTS: HRs contrasting CKD risk across arsenic exposure levels were estimated using Cox regression. Prevalence ORs for proteinuria (protein excretion ≥ 200mg/g) comparing quartiles of total urinary arsenic concentrations were estimated using logistic regression. RESULTS: We identified 1,104 incident kidney disease cases, including 447 CKD cases (incidence rates, 166.5 and 67.4 per 104 person-years, respectively). A dose-dependent association between well-water arsenic concentrations and kidney diseases was observed after adjusting for age, sex, education, body mass index, cigarette smoking, alcohol consumption, and analgesic use. Using arsenic concentration ≤ 10.0μg/L as reference, multivariable-adjusted HRs for incident CKD were 1.12 (95% CI, 0.88-1.42), 1.33 (95% CI, 1.03-1.72), and 1.33 (95% CI, 1.00-1.77) for arsenic concentrations of 10.1 to 49.9, 50.0 to 149.9, and ≥150.0μg/L, respectively (P for trend=0.02). The association between arsenic concentration and kidney diseases was stronger for women (P for interaction=0.06). Arsenic values in the range of 50th to 75th and 75th to 100th percentiles of total urinary arsenic concentrations were associated with 50% and 67% higher prevalences, respectively, of proteinuria. LIMITATIONS: Kidney diseases and CKD outcomes were based on diagnostic codes. Glomerular filtration rates were not available. Other heavy metals were not measured. CONCLUSIONS: This study describes the temporal relationship between arsenic concentrations ≥ 10μg/L in drinking water and CKD. A dose-dependent association between well-water arsenic concentration and kidney diseases was observed. Higher creatinine-adjusted urinary total arsenic concentrations were associated with a higher prevalence of proteinuria.
引用
- Hsu LI, Hsieh FI, Wang YH, et al. Arsenic Exposure From Drinking Water and the Incidence of CKD in Low to Moderate Exposed Areas of Taiwan: A 14-Year Prospective Study. Am J Kidney Dis. 2017. PMID: 28844585. doi:10.1053/j.ajkd.2017.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。